NASDAQ:SUPN Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $38.29 +0.15 (+0.39%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$37.42▼$39.0050-Day Range$35.23▼$42.0352-Week Range$24.95▼$42.09Volume448,844 shsAverage Volume426,952 shsMarket Capitalization$2.07 billionP/E Ratio59.83Dividend YieldN/APrice Target$47.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Supernus Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside22.7% Upside$47.00 Price TargetShort InterestBearish10.66% of Float Sold ShortDividend StrengthN/ASustainability-2.35Upright™ Environmental ScoreNews Sentiment-0.11Based on 6 Articles This WeekInsider TradingSelling Shares$3.24 M Sold Last QuarterProj. Earnings Growth-58.90%From $1.63 to $0.67 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 starsMedical Sector749th out of 1,026 stocksPharmaceutical Preparations Industry371st out of 504 stocks 2.5 Analyst's Opinion Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.00, Supernus Pharmaceuticals has a forecasted upside of 22.7% from its current price of $38.29.Amount of Analyst CoverageSupernus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.66% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently increased by 0.55%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSupernus Pharmaceuticals has received a 58.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topiramate", "Safinamide", "Oxcarbazepine", and "Amantadine" products. See details.Environmental SustainabilityThe Environmental Impact score for Supernus Pharmaceuticals is -2.35. Previous Next 1.6 News and Social Media Coverage News SentimentSupernus Pharmaceuticals has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Supernus Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SUPN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows1 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,239,325.00 in company stock.Percentage Held by InsidersOnly 8.70% of the stock of Supernus Pharmaceuticals is held by insiders.Percentage Held by Institutions99.82% of the stock of Supernus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to decrease by -58.90% in the coming year, from $1.63 to $0.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is 59.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 150.62.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is 59.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 163.13.Price to Book Value per Share RatioSupernus Pharmaceuticals has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Supernus Pharmaceuticals (NASDAQ:SUPN) StockSupernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.Read More Receive SUPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SUPN Stock News HeadlinesFebruary 8, 2023 | americanbankingnews.comJack A. Khattar Sells 13,532 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) StockFebruary 3, 2023 | americanbankingnews.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack A. Khattar Sells 976 Shares of StockFebruary 9, 2023 | Oxford Club (Ad)Dividend Expert Reveals His Biggest Income Secrets… Free of ChargeMarc Lichtenfeld –Author of the best-selling book Get Rich With Dividends – is giving away his Ultimate Dividend Package… Get His #1 Dividend Stock… The Safest 9% Dividend in the World… Top Three “Extreme Dividend” Stocks, And Much, Much MoreFebruary 2, 2023 | americanbankingnews.comStockNews.com Lowers Supernus Pharmaceuticals (NASDAQ:SUPN) to BuyJanuary 18, 2023 | finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) investors are up 3.6% in the past week, but earnings have declined over the last three yearsJanuary 3, 2023 | finance.yahoo.comHere’s Why Supernus Pharmaceuticals (SUPN) Outperformed in Q3December 23, 2022 | seekingalpha.comSUPN Supernus Pharmaceuticals, Inc.December 1, 2022 | finance.yahoo.comSupernus Pharma's Charts Are Looking SuperFebruary 9, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 22, 2022 | finance.yahoo.comSupernus to Present at the Piper Sandler 34th Annual Healthcare ConferenceNovember 11, 2022 | finance.yahoo.comSupernus Pharmaceuticals Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 8, 2022 | seekingalpha.comSupernus Pharmaceuticals, Inc. (SUPN) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comSupernus Pharmaceuticals (SUPN) Misses Q3 Earnings EstimatesNovember 8, 2022 | finance.yahoo.comSupernus Announces Third Quarter 2022 Financial ResultsNovember 2, 2022 | seekingalpha.comAxsome Therapeutics: All Eyes On Auvelity LaunchOctober 25, 2022 | finance.yahoo.comSupernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022October 10, 2022 | nasdaq.comFDA Declines To Approve Supernus Pharma's Parkinson's DrugOctober 10, 2022 | marketwatch.comSupernus Pharmaceuticals: FDA Turns Away SPN-830 ApplicationOctober 10, 2022 | finance.yahoo.comSupernus Provides Regulatory Update on SPN-830October 1, 2022 | fool.comSupernus Pharmaceuticals (NASDAQ: SUPN)September 7, 2022 | finance.yahoo.comSupernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?August 31, 2022 | finance.yahoo.comSupernus to Present at the 2022 Wells Fargo Healthcare ConferenceAugust 31, 2022 | finance.yahoo.comSupernus Pharmaceuticals Appears Ready for an Upside BreakoutAugust 13, 2022 | nasdaq.comIs Supernus Pharmaceuticals (NASDAQ:SUPN) A Risky Investment?August 11, 2022 | finance.yahoo.comThe past five years for Supernus Pharmaceuticals (NASDAQ:SUPN) investors has not been profitableAugust 8, 2022 | finance.yahoo.comBest Momentum Stocks to Buy for August 8thAugust 7, 2022 | seekingalpha.comSupernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2022 Results - Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SUPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SUPN Company Calendar Last Earnings11/03/2021Today2/08/2023Next Earnings (Estimated)4/12/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:SUPN CUSIP86845910 CIK1356576 Webwww.supernus.com Phone(301) 838-2500Fax301-838-2501Employees575Year FoundedN/APrice Target and Rating Average Stock Price Forecast$47.00 High Stock Price Forecast$47.00 Low Stock Price Forecast$47.00 Forecasted Upside/Downside+22.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.64 Trailing P/E Ratio59.83 Forward P/E Ratio23.49 P/E GrowthN/ANet Income$53.42 million Net Margins5.72% Pretax Margin4.20% Return on Equity4.51% Return on Assets2.24% Debt Debt-to-Equity RatioN/A Current Ratio0.91 Quick Ratio0.80 Sales & Book Value Annual Sales$579.78 million Price / Sales3.57 Cash Flow$1.85 per share Price / Cash Flow20.73 Book Value$15.43 per share Price / Book2.48Miscellaneous Outstanding Shares54,060,000Free Float49,355,000Market Cap$2.07 billion OptionableOptionable Beta0.99 Key ExecutivesJack A. KhattarPresident, CEO, Secretary & DirectorTimothy C. DecChief Financial Officer & Senior Vice PresidentFrank MottolaSenior VP-Quality, GMP Operations & ITPadmanabh P. BhattChief Scientific Officer & Senior Vice PresidentJonathan RubinChief Medical Officer & Senior Vice PresidentKey CompetitorsCorcept TherapeuticsNASDAQ:CORTPacira BioSciencesNASDAQ:PCRXPerrigoNYSE:PRGOCureVacNASDAQ:CVACFibroGenNASDAQ:FGENView All CompetitorsInsiders & InstitutionsSwiss National BankBought 2,500 shares on 2/8/2023Ownership: 0.239%Arizona State Retirement SystemBought 580 shares on 2/8/2023Ownership: 0.028%Texas Permanent School FundSold 2,133 shares on 2/7/2023Ownership: 0.067%Shell Asset Management Co.Sold 3,104 shares on 2/7/2023Ownership: 0.027%Commonwealth Equity Services LLCSold 1,518 shares on 2/7/2023Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions SUPN Stock - Frequently Asked Questions Should I buy or sell Supernus Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SUPN shares. View SUPN analyst ratings or view top-rated stocks. What is Supernus Pharmaceuticals' stock price forecast for 2023? 1 analysts have issued 12 month price targets for Supernus Pharmaceuticals' stock. Their SUPN share price forecasts range from $47.00 to $47.00. On average, they expect the company's stock price to reach $47.00 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View analysts price targets for SUPN or view top-rated stocks among Wall Street analysts. How have SUPN shares performed in 2023? Supernus Pharmaceuticals' stock was trading at $35.67 on January 1st, 2023. Since then, SUPN shares have increased by 7.3% and is now trading at $38.29. View the best growth stocks for 2023 here. When is Supernus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 12th 2023. View our SUPN earnings forecast. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced its quarterly earnings data on Wednesday, November, 3rd. The specialty pharmaceutical company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.21 by $0.19. The specialty pharmaceutical company earned $148.46 million during the quarter, compared to the consensus estimate of $141.32 million. Supernus Pharmaceuticals had a net margin of 5.72% and a trailing twelve-month return on equity of 4.51%. During the same quarter in the previous year, the firm earned $0.74 EPS. What guidance has Supernus Pharmaceuticals issued on next quarter's earnings? Supernus Pharmaceuticals updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $650.00 million-$680.00 million, compared to the consensus revenue estimate of $674.36 million. What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO? 20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees. What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA). What is Supernus Pharmaceuticals' stock symbol? Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN." Who are Supernus Pharmaceuticals' major shareholders? Supernus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (2.97%), Rice Hall James & Associates LLC (1.15%), Congress Asset Management Co. MA (0.94%), International Biotechnology Trust PLC (0.71%), Tributary Capital Management LLC (0.63%) and Scout Investments Inc. (0.57%). Insiders that own company stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Tami Tillotson Martin. View institutional ownership trends. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Supernus Pharmaceuticals' stock price today? One share of SUPN stock can currently be purchased for approximately $38.29. How much money does Supernus Pharmaceuticals make? Supernus Pharmaceuticals (NASDAQ:SUPN) has a market capitalization of $2.07 billion and generates $579.78 million in revenue each year. The specialty pharmaceutical company earns $53.42 million in net income (profit) each year or $0.64 on an earnings per share basis. How many employees does Supernus Pharmaceuticals have? The company employs 575 workers across the globe. How can I contact Supernus Pharmaceuticals? Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The official website for the company is www.supernus.com. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at gpatrick@supernus.com, or via fax at 301-838-2501. This page (NASDAQ:SUPN) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.